Open AccessCytokine-induced killer cell delivery enhances the antitumor activity of oncolytic reovirus
Author(s) -
Xing Zhao,
Wei Ouyang,
Cariad Chester,
Shiqi Long,
Nianxue Wang,
Zhisong He
Publication year - 2017
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0184816
Subject(s) - oncolytic virus , cytokine induced killer cell , immune system , immunotherapy , cytotoxic t cell , flow cytometry , cytokine , biology , virology , cancer immunotherapy , antibody , cytotoxicity , cancer research , cancer cell , immunology , cancer , cd8 , in vitro , cd3 , biochemistry , genetics
Oncolytic viruses (OV) have recently emerged as a promising therapeutic modality in cancer treatment. OV selectively infect and kill tumor cells, while sparing untransformed cells. The direct cytotoxic effects combined with the capacity to trigger an immune response make OV an appealing combination partner in the burgeoning field of cancer immunotherapy. One of the leading OV therapeutic candidates is the double-stranded RNA virus reovirus. In order to improve the oncolytic activity of reovirus and allow for systemic administration despite the prevalence of neutralizing antibodies, cytokine-induced killer (CIK) cells were explored as cell carriers for reovirus delivery. In this study, CIK cells were successfully loaded with reovirus ex vivo , and viral replication was limited in CIK cells. Confocal microscopy and flow cytometry demonstrated that CIK cells retained reovirus on the surface. Moreover, CIK cells could promote reovirus infection of tumor cells in the presence of neutralizing antibodies; meanwhile, cytotoxicity of CIK cells was increased after loading with reovirus. These findings support further investigation of reovirus and CIK combination for antitumor therapy.